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Abstract

The incidence of melanoma in the United States continues
to rise. Head and neck melanomas comprise approximately
20% of all primary cutaneous melanomas. Sentinel lymph
node (SLN) biopsy (SLNB) has become the standard of care
for staging in melanoma. It has a number of advantages,
including the addition of prognostic information, accurate
staging, and the potential to add completion lymph node
dissection (CLND) or adjuvant therapy when indicated.
Furthermore, it may allow for the identification of patients
who would benefit from inclusion in clinical trials; this
advantage may be amplified based on the introduction of
novel targeted therapies.
SLNB does have some disadvantages in head and neck
melanomas. The complex lymphatic drainage and anatomy
of the head and neck can result in some technical challenges.
SLN positivity rates in head and neck melanoma are lower
than for trunk or extremity melanoma; despite this, overall
and disease free survival rates are lower in head and neck
melanoma.
This review examines the literature evidence for the efficacy
of SLNB in head and neck melanoma, and in particular
attempts to estimate five variables: the likelihood of finding a
SLN, the number of SLNs found, the likelihood of a positive
SLN, the likelihood of identifying positive non-sentinel
lymph nodes on CLND, and the likelihood of recurrence in
the neck despite a negative SLNB.
Overall, despite the technical challenges inherent in SLNB
when applied to head and neck melanoma, it remains a
technically feasible and effective procedure in this anatomic
site. (J Patient-Centered Res Rev. 2014;1(1):27-32.)

Keywords

melanoma, head and neck, sentinel lymph node biopsy
Correspondence: Martin Corsten, MD, FRCSC
University of Ottawa/The Ottawa Hospital, Suite S-3,
501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6
Phone: 613-798-5555, ext. 72968, Fax: 613-739-6542
Email: mcorsten@toh.on.ca
Reviews

Introduction

The incidence of melanoma in the United States continues to
rise, with an estimated 76,690 new cases and 9,480 deaths in
2013 alone.1 Although the incidence is increasing, survival
is also improving over time, likely due to earlier detection.
Head and neck melanoma represents 20% of all primary
cutaneous melanomas.2 Prognostic factors for head and neck
melanoma include a patient’s age,3 sex,4 depth of tumor,5
ulceration,6 number of mitotic factors per high power field,7
specific location of tumor site8,9 and most importantly the
sentinel lymph node (SLN) status.
First introduced in 1992 by Morton,10 sentinel lymph node
biopsy (SLNB) has become the standard of care for staging
in head and neck melanoma patients. This technique of
lymph node mapping was created as a minimally invasive
alternative to elective lymph node dissection for nodal
staging. It allows for detection of patients with occult nodal
metastases who may benefit from a completion lymph
node dissection (CLND). The procedure can be performed
in one of two ways (or as a combination): preoperatively
using a radiotracer (usually technetium 99m (Tc99)), or
intraoperatively using Isosulfan blue dye. Several studies
have shown that using a combination of the two methods
improves results.11,12 The idea is that either technique will
identify the first echelon lymph node(s) draining the tumor
site.13 Many centers also use preoperative mapping with the
addition of single photon emission CT (SPECT) to determine
the location of the lymph node prior to surgery.
Intraoperatively, four injections are made using Isosulfan
blue dye around the primary tumor. Next, wide local excision
of the primary tumor is performed. At this point the surgeon
makes an incision over the area identified preoperatively by
lymphoscintigraphy and dissection is performed to identify
the blue-stained lymph node(s). The handheld gamma
probe is used to confirm the SLN by its high counts and the
subsequent presence of only background radiation once the
node or nodes have been removed.13 Pathologic analysis
is performed and if metastatic melanoma is present in the
lymph node(s) the patient is a candidate for a CLND of the
adjacent nodal basins in the ipsilateral neck.
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Unfortunately, SLNB in the head and neck does have some
limitations. Many of these are related to the more complex
lymphatic drainage in the head and neck, compared to the
extremities or trunk. This complexity has raised concerns
about the reliability of SLNB in the setting of head and
neck melanoma to accurately reflect the status of the entire
nodal basin. Cervical lymphatic drainage is interlacing and
can be watershed in nature; at least one-third of primary
melanomas of the head and neck will show drainage to
nodal basins outside the parotid bed and/or neck levels
that are usually dissected when performing elective nodal
dissections. O’Brien et al.14 demonstrated this complexity of
lymphatic drainage in the head and neck by reporting a 34%
discordance between the clinical prediction of lymphatic
drainage and lymphoscintigraphy findings in 97 cases of
head and neck cutaneous melanoma.
Another potential pitfall with the use of SLNB for head and
neck melanoma is the possibility of a “false-negative” result.
Patients with negative SLNs are considered unlikely to have
nodal metastatic disease, and therefore may not be offered
follow-up CLND or adjuvant therapy. Various authors have
described “false-negatives” for SLNB in the head and neck
in different ways; some report any nodal recurrence after a
negative SLNB as a “false-negative,” while others report
only “in-basin” nodal recurrence. Still others exclude nodal
recurrence as a “false-negative” if it occurs in conjunction
with local or distant recurrence. This makes the reporting
of “false-negatives” difficult to compare across studies.
What is agreed upon is that SLNB in the head and neck has
lower rates of positive SLNs than SLNB used for trunk or
extremity melanoma.15 In addition, despite the fact that SLN
positivity is a strong negative prognostic factor for survival
in melanoma, head and neck melanomas have lower rates of
disease-free and overall survival.15,16 This implies a higher
rate of “false-negatives” for head and neck melanoma than
melanomas in other anatomical sites.
The head and neck is a relatively small area of the body that
contains arguably the most complex anatomy. The potential
for damage to important anatomic structures is a real and
serious concern in the setting of all procedures in the head
and neck, but perhaps more so in the setting of SLNB due
to limited surgical exposure. If the SLN is contained within
the parotid bed, a superficial parotidectomy may be required
in order to adequately expose and preserve the facial nerve,
which adds to the risk of the procedure and operative time.
Perhaps the most important limitation of SLNB is the fact
that CLND following detection of a positive SLN has not
28
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been proven to improve survival. Several studies have
shown that there is no significant difference in disease-free
or disease-specific survival between patients with melanoma
who undergo SLNB alone compared with those that have a
CLND.17,18 In fact, Bilimora et al. used the National Cancer
Data Base in the United States and found that only 50%
of patients in the United States who have a positive SLNB
undergo a CLND.19 Arguments for CLND include regional
disease control and accurate staging.
Despite the above limitations, most clinicians agree that
SLNB in the setting of head and neck cutaneous melanoma
remains the standard of care. It is well established that
the status of the SLN is the most important predictor of
survival in patients with melanoma.20 Thus, SLNB acts as an
important diagnostic staging procedure to facilitate further
treatment for patients with head and neck melanoma. In
particular, it allows for early CLND for management of neck
metastasis. As a staging procedure SLNB allows clinicians
to stratify patients when reporting treatment outcomes and/
or when grouping patients within clinical trials. Finally, the
approval by the Federal Drug Administration (FDA) in the
United States of targeted therapies for melanoma represents
the most important advancement in melanoma treatment
in decades. Currently, the anti-CLA4 blocking antibody
ipilimumab and the BRAF inhibitor vemurafenib are FDAapproved, with other molecularly targeted antibodies such as
dabrafenib (BRAF), trametinib (anti-MEK), and salumetinib
(anti-MEK) potentially available in the near future.21 The
exact role for these targeted therapies in the adjuvant setting
is the subject of current clinical trials; stratification of patients
to identify those at high risk for recurrence (as SLNB does)
is critical for their appropriate inclusion in these trials. With
further development of these exciting treatments SLNB may
well play a critical role in personalized treatment for patients
with melanoma.
In 2011, de Rosa et al. published a systematic review of
the use of SLNB in head and neck melanoma.22 This paper
reported on the published literature up to and including
2009, and reported a number of important variables that
could be used to evaluate the benefits of SLNB in head and
neck melanoma, including the likelihood of identification of
a SLN, the median number of SLNs identified, the rate of
SLN positivity, the incidence of positive non-sentinel lymph
nodes (NSLNs) found during CLND, and the incidence
of recurrence in the neck despite a negative SLNB. They
identified a trend toward an increased SLN identification
rate (a key component to successful use of SLNB in
melanoma) in studies published in later years. The purpose
Reviews

of this current review is to update the results of the de Rosa
systematic review using publications since 2009, as part of
an ongoing assessment of the efficacy of SLNB for head and
neck melanoma.

Table 1. Rate of identification of a sentinel lymph node (SLN).
Author

Year

Patients

SLN
identification rate

de Rosa22*

2011

3,442

95%

Author

Year

Patients

SLN
identification rate

Patuzzo23

2013

331

98%

Saltman24

2010

236

92%

Parrett25

2012

365

99%

Erman26

2012

353

100%

Miller27

2011

153

98%

Jensen28

2013

137

97%

1,575

98%

Methods

Search Strategy
A computerized literature search was performed using Ovid,
Medline, Embase, and PubMed databases using the terms
“melanoma,” “head and neck neoplasms,” “head and neck
cancer,” “sentinel lymph node” and “sentinel lymph node
biopsy.” The results were limited to English publications
from 2010 to September 13, 2013. Once duplicates were
identified and removed, the retrieved articles were then
reviewed to ensure their relevance for our review. Once all
articles to be included were identified, the references of all
included articles were reviewed to identify any additional
applicable publications that may have been missed by our
original search.
Inclusion & Exclusion Criteria
Inclusion criteria consisted of studies:
a. completed in 2010 or later
b. with 100 or more patients
c. that report clearly the following outcomes of SLNB for
cutaneous malignant melanoma of the head and neck:
i. likelihood of identifying a SLN
ii. number of SLNs identified
iii. odds of detecting a positive SLN
iv. identification of positive non-sentinel nodes during
completion neck dissection
v. risk of nodal recurrence after negative SLNB
Studies were excluded if they did not meet the above
inclusion criteria resulting in a total of 12 included studies.
See Figure 1 for Consort diagram.

Results

1. Likelihood of identifying a sentinel lymph node
In a meta-analysis of 3,442 patients from 32 studies up to
2009, de Rosa et al. reported the identification of at least one
SLN in 95% of cases.22 Several other authors have published
individual institution reviews since 2009 (Table 1). The range
of SLN identification rates for head and neck melanoma in
these more recent reports, when averaged together, showed
a 98% rate in 1,575 patients. These reports confirm the fact
that, despite the complex lymphatic drainage in the head
and neck, in the vast majority of cases at least one SLN is
identified during SNLB for head and neck melanomas.
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Total/
Weighted
Average

*de Rosa is a meta-analysis of 32 studies. The others are single
institution studies.

2. Number of sentinel lymph nodes identified
A number of authors have reported on the average number of
SLNs identified during SLNB for head and neck melanoma
(Table 2). de Rosa reported a median of 2.6 SNs per patient
in her 2009 systematic review. Three subsequent individual
series have published mean SLN harvest rates ranging from
a low of 1.6 to a high of 3.7; the weighted average of these
subsequent series was 2.5 in 1,070 patients. Thus, there is
evidence that roughly 2-3 sentinel nodes are obtained on
average during SLNB for head and neck melanoma.
Table 2. Number of sentinel lymph nodes identified.
Number
of Patients

Median
or Mean

SLNs
per patient

3,442

Median

2.6

Number
of Patients

Median
or Mean

SLNs
per patient

Patuzzo23

331

Mean

1.6

Parrett25

365

Mean

3.7

Jensen28

137

Mean

2.6

Al Ghazal29

237

Mean

1.9

1,070

Mean

2.5

Author
de Rosa22

Author

Total/Weighted
Average
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3. Odds of detecting a positive sentinel node
In her 2009 systematic review, de Rosa published a 15%
rate of identifying at least one positive SLN during SLNB
for head and neck melanomas. A number of authors have
added their single institution reports to this literature since
2009 (Table 3). The odds of a positive sentinel node in these
reports ranged from 9–20%, and the weighted average was
14% in a total of 2,450 patients.
Table 3. Odds of detecting a positive SLN
Author
de Rosa22

Number
of Patients

Rate of + SLN

3,442

15%

Number
of Patients

Rate of + SLN

Patuzzo23

331

18%

Saltman24

216

13%

Parrett25

365

11%

Martin30

339

14%

Fadaki16

360

11%

Author

Jensen

28

Al Ghazal

137

9%

29

237

20%

31

315

15%

150

12%

2,450

14%

McDonald
Miller

27

Total/Weighted
Average

4. Identification of positive non-sentinel nodes during
completion neck dissection
In the presence of a positive SLN, the standard treatment
is to perform an ipsilateral CLND. Recent literature has
questioned the necessity for a CND in this scenario; an
important consideration in this decision is the probability
that other NSLNs are found to contain cancer during this
dissection. In her systematic review, de Rosa reported that
in 12 evaluable studies, 14% of cases contained positive
NSLNs; the total number of evaluable cases was not reported.
We identified six subsequent papers in which the rate of
positive non-sentinel nodes in CLND was evaluable (Table
4); the rate ranged from 21–39%, and the weighted average
was 27% in 249 neck dissections. This was the only variable
which showed a significant discrepancy between de Rosa’s
meta-analysis and the subsequent cases series published in
the literature.
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Table 4. Odds of detecting positive NSLNs on CND
Number
of Patients

Rate of + NSLN

3,442

14%

Number
of Patients

Rate of + NSLN

Gyorki32

36

22%

Patuzzo23

59

39%

Parrett25

37

22%

26

68

25%

Al Ghazal29

31

21%

Miller27

18

22%

Total/Weighted
Average

249

27%

Author
de Rosa

22

Author

Erman

5. Risk of nodal recurrence after negative SNB
Head and neck melanomas are known to have higher
recurrence rates despite a negative SLNB than trunk or
extremity melanomas. As described earlier, different authors
have reported “false-negative” rates for SLNB in head and
neck melanoma differently. We restricted our analysis to
the description of nodal recurrence (of any kind, with or
without other sites of recurrence) after a negative sentinel
node biopsy.
In de Rosa’s systematic review, the overall incidence of
nodal recurrence after a negative SNB was 5%; again, the
overall number of patients was not reported. In five large
series published since then, very similar and quite uniform
rates of such nodal recurrence have been identified (Table 5),
ranging from 4–7%; the weighted average was 6% in 1,202
patients.
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Table 5. Rate of nodal recurrence despite a negative SLNB
Author
de Rosa

22

Author
Saltman

24

Number
of Patients

Nodal Recurrence

3,442

5%

Number
of Patients

Nodal Recurrence

190

6%

25

325

5%

Erman26

283

7%

137

4%

267

6%

1,202

6%

Parrett

Jensen

28

McDonald31
Total/
Weighted
Average

Discussion

Sentinel lymph node biopsy has been an important element
in the treatment of melanoma since Morton’s landmark paper
in 1992.10 While it has not demonstrated improved overall
and disease-specific survival, the use of SLNB has a number
of advantages over observation alone, including the addition
of valuable prognostic information, the ability to restrict
CLND to patients likely to benefit from it, the improvement
of regional control, and the identification of high-risk patients
that may benefit from adjuvant therapy and/or inclusion in
clinical trials. The advent of a new generation of targeted
therapies may well enhance the therapeutic benefit of SLNB,
as studies of the benefit of these therapies in the adjuvant
setting become available.
Despite a number of challenges that are unique to the head
and neck, including more complex lymphatic drainage
patterns and specific anatomic issues (for example, the facial
nerve in parotid SLNB), head and neck SLNB as a technical
exercise remains extremely feasible. Improvements such as
pre-operative localization using SPECT/CT fusions have
allowed for the successful intraoperative identification
of at least one SLN in nearly 100% of cases, and rates of
successful SLN identification seem to be increasing with
time. Overall, an average of two to three SLNs are identified
in the typical head and neck melanoma case, and at least
one positive SLN is identified roughly 15% of the time.
While the “false-negative” rate for SLNB in head and neck
melanoma is higher than in other anatomical sites, a negative
SLNB is associated with later nodal recurrence in the neck
only about 5% of the time.
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A remaining controversy relates to the utility of CLND in
the presence of a positive SLNB. Multiple authors have
shown that, in the presence of a positive SLN, other, nonsentinel lymph nodes will be found on CLND in head and
neck melanoma roughly 15-25% of the time. Certainly, one
would expect to see a benefit from CLND in these cases, but
such a benefit has not been conclusively and reproducibly
demonstrated in studies. The second Multicenter Selective
Lymphadenectomy Trial (MSLT-II) is a randomized Phase
III trial of SLNB plus CLND vs. SLNB plus ultrasound
observation of the lymph nodes in patients with positive
SLNs detected by histopathologic or molecular techniques.33
MSLT-II’s primary outcome is melanoma-specific survival,
while the secondary outcomes include overall and diseasefree survival, prognostic accuracy of histopathologic,
molecular, and immunologic markers, and quality of life.
The trial opened in 2005 with an aim to enroll 1,925 subjects.
This trial could help to better delineate the situations in
which CLND after positive SLNB would be beneficial to
the patient.

Conclusions

Sentinel lymph node biopsy is a technically feasible and
safe procedure for head and neck melanoma. It has multiple
advantages, including the addition of prognostic information,
the potential for adding CLND, and the identification of
patients who would benefit from adjuvant therapy and/or
inclusion in clinical trials. It remains an important element
of treatment for head and neck melanomas.
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